Suppr超能文献

原头蚴P29 DNA疫苗对Balb/c小鼠实验性囊型棘球蚴病的免疫作用

The Immunization of Protoscolices P29 DNA Vaccine on Experimental Cystic Echinococosis in Balb/c Mice.

作者信息

Gharibi Zahra, Rahdar Mahmoud, Pirestani Majid, Tavalla Mehdi, Tabandeh Mohammad-Reza

机构信息

Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Parasitology Department, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

出版信息

Acta Parasitol. 2021 Dec;66(4):1114-1121. doi: 10.1007/s11686-021-00367-7. Epub 2021 Apr 3.

Abstract

PURPOSE

Cystic Echinococosis is one of the important parasitic diseases that is considered as a problem economics and health in many parts of the world. Many efforts have been performed for controlling the disease in the world. To reach a reliable vaccine against Cystic Echinococosis is one of the important duty of governments. Several antigen of hydatid cyst for vaccine candidate have been evaluated. In this study, P-29 antigen has been used for this purpose.

METHODS

E.g P29 antigen was cloned in Escherichia coli and transfected into the Chinese hamster ovary cell for antigen proliferation and used for vaccination in Balb/c mice. The recombinant antigen E.g-29 was shown using Western blot test. Two dilution of DNA vaccine (pCEgP-29) including 50 µg/100 µl and 100 µg/100 µl were prepared. Twenty four Balb/C male 6-8 week mouse were divided in 4 groups. The groups were included in 2 vaccination groups (pcEg.P29 50 µg/100 µl and 100 µg/100 µl dilution) as immunized groups and 2 groups of plasmid and PBS as control. The mice were injected intramuscularly 3 times with 2 weeks interval. After 3 weeks from last injection, all groups were challenged intraperitonealy with 2000 protoscolices. After 5 months, the mice were euthanized by ketamine/xylasine injection and number, size, and weight of cysts were recorded.

RESULTS

Immunization rate was up to 93% in vaccinated group when compared with the control group.

CONCLUSION

The results of this study showed that rEg.P29 could be considered as an effective vaccine for controlling of E. granulosus prevalence in intermediated host.

摘要

目的

囊型包虫病是一种重要的寄生虫病,在世界许多地区被视为经济和健康问题。世界上为控制该疾病做出了许多努力。研发一种可靠的抗囊型包虫病疫苗是各国政府的重要职责之一。已对几种用于候选疫苗的包虫囊肿抗原进行了评估。在本研究中,P-29抗原被用于此目的。

方法

例如,P29抗原在大肠杆菌中克隆并转染到中国仓鼠卵巢细胞中进行抗原增殖,然后用于Balb/c小鼠的疫苗接种。通过蛋白质印迹试验展示重组抗原E.g-29。制备了两种浓度的DNA疫苗(pCEgP-29),分别为50μg/100μl和100μg/100μl。将24只6-8周龄的Balb/C雄性小鼠分为4组。这些组包括2个疫苗接种组(pcEg.P29 50μg/100μl和100μg/100μl稀释液)作为免疫组,以及2组质粒和PBS作为对照组。小鼠每隔2周肌肉注射3次。在最后一次注射后3周,所有组腹腔注射2000个原头蚴进行攻击。5个月后,通过注射氯胺酮/赛拉嗪使小鼠安乐死,并记录囊肿的数量、大小和重量。

结果

与对照组相比,疫苗接种组的免疫率高达93%。

结论

本研究结果表明,rEg.P29可被视为控制中间宿主中细粒棘球绦虫流行的有效疫苗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验